复兴疗法公司扩大了美国和加拿大的布西拉专利,涵盖神经毒剂保护和传染病用途. Revive Therapeutics expanded U.S. and Canadian patents for bucillamine, covering nerve agent protection and infectious disease uses.

复兴疗法公司已扩大其对美国和加拿大的布西拉的专利保护,涵盖其用于神经毒剂暴露的用途,并授予加拿大传染病应用专利. Revive Therapeutics has expanded its patent protection for bucillamine in the U.S. and Canada, covering its use against nerve agent exposure and granting a Canadian patent for infectious disease applications. 该药物已在日本和韩国数十年来用于风湿类关节炎,显示出神经保护和抗氧化效应的潜力,包括通过谷甘地酮补充和Nrf2路径激活。 The drug, already used for decades in Japan and South Korea for rheumatoid arthritis, shows potential for neuroprotection and antioxidant effects, including through glutathione replenishment and Nrf2 pathway activation. 该公司与加拿大DRDC Suffield研究中心正在进行的研究可能支持进一步应用有机磷酸酯中毒、创伤性脑损伤、病毒感染和长期COVID,从而加强其在公共卫生和生物防御方面的作用。 The company’s ongoing research with Canada’s DRDC Suffield Research Centre may support further applications in organophosphate poisoning, traumatic brain injury, viral infections, and long COVID, strengthening its role in public health and biodefense.